9 results
Direct-acting oral anticoagulants (DOACs) for VTE treatment and prevention - Comparison Table

#DOAC #Anticoagulants #Anticoagulation #VTE #Management
anticoagulants (DOACs ... ) for VTE treatment ... Comparison Table #DOAC ... Anticoagulants #Anticoagulation ... #VTE #Management
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
algorithm for the treatment ... of cancer-associated ... body mass index; VTE ... #DOAC #VTE #Malignancy ... #Anticoagulation
Lower Extremity Venous Thrombosis - Management and Anatomy

Deep - Superficial - Active Bleeding

#LowerExtremity #Veins #Venous #Thrombosis
Lower Extremity ... Superficial #Deep #VTE ... Management #Anatomy #Anticoagulation
Treatment algorithm for VTE in Malignancy

(A) Suggested treatment algorithm for symptomatic and incidental DVT or PE
for VTE in Malignancy ... thrombosis in cancer ... DOAC, direct oral ... #DOAC #VTE #Malignancy ... #Anticoagulation
(DOAC interactions) Cancer-treatment specific inducers (↑) and inhibitors (↓)
of cytochrome p450 CYP3A4 and P-glycoprotein.

DOACs are substrates
(DOAC interactions ... ) Cancer-treatment ... DOACs are substrates ... metabolization of DOACs ... thereby leading to lower
Clotmaster Consensus 2019: Duration of Therapy for Venous Thromboembolic Disease
 • Superficial Venous Thrombosis
 • Upper
- Two or more lower ... Thrombophilia • Cancer ... DeLoughery @Bloodman #VTE ... #anticoagulation ... hematology #length #treatment
Longterm Venous Thromboembolism Treatment Algorithm
Treat for 3 months and reassess
 • Isolated distal DVT (without cancer)
Thromboembolism Treatment ... at 3 Months • Cancer ... therapy - Second VTE ... Thromboembolism #Treatment ... management #hematology #anticoagulation
Peripartum Cardiomyopathy - Summary
1. Definition
 • Towards the end of pregnancy to 5 months postpartum
Avoid Warfarin and DOAC ... suggest prophylactic anticoagulation ... Serial TTE and close ... management #cardiology #treatment
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

https://www.nejm.org/doi/full/10.1056/NEJMoa1711948

Authors’ Conclusions: “Oral edoxaban was noninferior to subcutaneous dalteparin
Edoxaban for the Treatment ... of Cancer-Associated ... thromboembolism was lower ... respect to recurrent VTE ... VenousThromboembolism #VTE